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Technical NoteUltrarapid Evaluation of Meningioma Malignancy by Intraoperative Flow CytometryGo Matsuoka1, Seiichiro Eguchi1, Hidenori Anami3, Tatsuya Ishikawa1, Koji Yamaguchi1, Masayuki Nitta1,
Yoshihiro Muragaki1,2, Takakazu Kawamata1-BACKGROUND: The prognosis for World Health Orga-
nization (WHO) grade II/III meningiomas is worse than for
WHO grade I meningiomas. Histopathologic grade should
ideally be identified during tumor resection, but current
methods are time-consuming and have doubtful reliance.
The aim of this study was to evaluate intraoperative flow
cytometry (iFC) as a method for providing ultrarapid eval-
uation of meningioma malignancy.
-METHODS: A total of 117 meningiomas were analyzed
with iFC during surgery. For each, the malignancy index
(MI) was calculated as the number of cells with a greater
than normal DNA content as a proportion of the total
number of cells. Each specimen was investigated histo-
pathologically and was diagnostically graded according to
the 2016 WHO grading system. MI results were compared
with WHO grades of the meningiomas.
-RESULTS: The automatic measurement of iFC took
approximately 9 minutes on average. The difference in MI
between grade I and grade II/III meningiomas was statis-
tically significant (P < 0.001). Receiver operating charac-
teristic analysis provided an optimal cutoff MI value of
8.0% for discrimination between grade I and grade II/III
groups, with 64.7% sensitivity and 85.0% specificity for
grade II/III meningiomas.
-CONCLUSIONS: Our method of calculating MI with iFC
appears to be technically feasible and reliable for ultrarapid
evaluation of meningioma malignancy. MI with iFC could
potentially enable determination of an optimal treatmentKey words
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- Ki-67 immunohistochemistry
- Malignancy index
- Meningioma
- MIB-1 index
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320 www.SCIENCEDIRECT.com WORLD NEstrategy during surgery, such as extent of resection of the
tumor and management of invaded normal brain or nerves.INTRODUCTIONhe best treatment goal for meningiomas is gross total
removal, which results in a longer recurrence-free periodT and improved overall survival.1 However, even after
complete resection, nonbenign World Health Organization
(WHO) grade II/III meningiomas, which include atypical and
anaplastic meningiomas, frequently recur,2 with recurrence 8
times more likely than for WHO grade I meningiomas.3
Furthermore, grade II meningiomas tend to grow more
aggressively when they recur than at their initial presentation.4
Radical resection during the initial surgery is therefore required,
particularly for grade II/III meningiomas. However, it is unusual
for the WHO grade of a meningioma to be established during
the initial surgery, partially because of the difficulty and the
time required for making such an assessment. A rapid and
reliable intraoperative method for evaluating the malignancy of
meningiomas could be of crucial importance. Identification of
histopathologic malignancy during tumor resection could help
the surgeon determine the optimal treatment strategy for the
patient, such as the extent of resection of tumors and the
management of invaded normal brain tissue or nerves, thus
providing the best chance of long-term tumor control.
Several reports have described new intraoperative methods for
determination of meningioma malignancy using flow cytometry
and Ki-67 immunohistochemistry; however, most of them are
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TECHNICAL NOTEmalignancy evaluation.5-14 Shioyama et al.15 reported a method
that used intraoperative flow cytometry (iFC) for rapid evaluation
of the malignancy of a glioma, allowing an assessment within 10
minutes. The aim of the present study was to evaluate the
feasibility and efficacy of applying iFC to establish the WHO
histopathologic grade of intracranial meningiomas during
resection using fresh material and a new technique in a shorter
evaluation period than that of Shioyama et al.15
MATERIALS AND METHODS
Patients
The experimental protocol was approved by the ethics com-
mittee of our institution (3014-R), and the study was con-
ducted in accordance with the principles of the Declaration of
Helsinki. All patients provided written informed consent.
Between November 2014 and March 2017, we resected
meningiomas in 138 consecutive patients at our institution.
Of these patients, 21 were excluded from the investigated
prospective cohort because of technical errors or insufficient
specimens for 1 or more of the studies. Thus, the analysis
included 117 patients. All were Asian, and 82 (70%) were
women. Median age at surgical treatment was 55.8  13.6
years (interquartile range, 46e67 years).
The senior author (T.K.) removed the tumor and determined the
extent of resection of each tumor. The diagnosis ofmeningioma
andfinalWHOgradewereconfirmedhistopathologically, andan
immunohistochemistry evaluation of the monoclonal antibody
Ki-67, a marker of proliferation, was performed. We reviewed
the pathologic diagnosis according to the criteria listed in the
WHO 2016 classification.16 In addition, we prospectively
collected information about each patient’s clinical history,
neuroimaging, and microsurgical dissection findings.
iFC Analysis
The technique of iFC was previously applied by Shioyama
et al.15 to cases of intracranial glioma. In this study, we
adopted a similar method but with new-generation equip-
ment, which resulted in improved automation and a shorter
procedure time. The first author (G.M.) performed the iFC
measurement for all cases. After the tumor was exposed,
tumor tissue specimens, each with a volume of approxi-
mately 2 mm,3 were obtained using forceps. The specimens
were placed in a test tube with a DNA staining reagent and
set in the FCM-2200 Celltac Peak analyzer (Nihon Koden,
Tokyo, Japan). Cell isolation initiated automatically. Staining,
cell counting, and DNA analysis were also automatic, with the
complete process taking 9 minutes. Human peripheral blood
cells were used as a reference for the DNA histogram anal-
ysis and for defining the position of the diploid G0/G1 peak in
the DNA histograms. The malignancy index (MI) was calcu-
lated as the ratio of the number of cells with a greater than
normal DNA content to the total number of cells.15
Histopathologic Analysis
Three neuropathologists analyzed the intraoperative frozen
and permanent tissue samples, reached a consensus opinion,
and decided the final histopathologic diagnosis; all 3 wereWORLD NEUROSURGERY 120: 320-327, DECEMBER 2018blinded to the calculated MI. The resected tumors were fixed
and embedded in paraffin and stained with hematoxylin and
eosin. Their proliferative activity was assessed by Ki-67
immunohistochemistry. When a differential diagnosis for le-
sions such as hemangiopericytoma and solitary fibrous tu-
mors was needed, signal transducer and activator of
transcription immunohistochemistry was additionally
performed.
Statistical Analysis
JMP 13 software (SAS Institute Inc., Cary, North Carolina,
USA) was used for statistical analysis. The relationship be-
tween intraoperative MI values and postoperative WHO
gradeswas evaluated. The patients were divided into 2 groups
according toWHOgrade I and grade II/III. Grades II and III were
grouped together because there were only 4 grade III cases,
which was insufficient to allow significance in the statistical
analysis. Differences between the 2 groups were assessed
using c2 tests for categorical variables and one-way analysis of
variance for continuous variables. P < 0.05 was considered
significant. Logistic regression analysiswas used to establish a
statistical model of the relationship between WHO grades (as
the dependent variable) and MI (as the explanatory variable).
Receiver operating characteristic (ROC) analysis was applied,
with grade II/III meningioma taken as positive and grade I
meningioma taken as negative, and the area under the ROC
curve was measured. The optimal cutoff value of MI for
discriminating grade II/III meningiomas from grade I meningi-
omas was evaluated by the Youden index, and its sensitivity
and specificity were calculated.
RESULTS
Meningiomas
Table 1 summarizes the demographic characteristics of the
patients included in this study. Of 117 patients, 83 (71.0%) had
grade I meningiomas, 30 (25.7%) had atypical meningiomas
(grade II), and 4 (3.4%) had anaplastic meningiomas (grade III).
There were 13 recurrent meningiomas (Table 2). Grade I tumors
included 28 meningothelial, 26 fibrous, 19 transitional, 2
microcystic, 1 psammomatous, 4 angiomatous, and 3
unclassifiable meningiomas. The locations of the tumors were as
follows: convexity (n ¼ 29), falcine (n ¼ 18), parasagittal (n ¼ 8),
skull base (n ¼ 58), and intraventricular (n ¼ 4). The iFC analysis
was completed in 9 minutes.
Outcomes
There was a statistically significant difference in mean MI values
for the grade I and grade II/III groups (6.08%  0.86% vs. 14.1%
 1.35%; P < 0.001) and for the grade I and grade II groups
(6.08%  0.86% vs. 12.5%  11.2%; P < 0.001). The ROC
analysis indicated that an MI of 8.0% was the optimal cutoff
value for distinguishing between the 2 groups (WHO grade I and
grade II/III), with 64.7% sensitivity and 85.0% specificity
(Figure 1).
Illustrative Case 1
A 33-year-old man presenting with headache was referred to our
outpatient clinic. Magnetic resonance imaging of the head
showed a tumor that extended along the cerebral falx andwww.WORLDNEUROSURGERY.org 321
Table 1. Clinical and Demographic Characteristics of Patients Who Underwent Tumor Removal for Intracranial Meningioma
WHO
Grade I (n [ 83)
WHO
Grade II/III (n [ 34) P Value
WHO
Grade II (n [ 30) P Value
WHO
Grade III (n [ 4)
Age, years* 56.2  11.7 55.6  2.3 0.83 54.0  18.2 0.47 63.0  12.2
Sex
Female 61 (73.5%) 21 (61.8%) 18 3
Male 22 (16.5%) 13 (38.2%) 12 1
Localization
Convexity 20 8 7 1
Falx 13 5 5
Parasagittal 3 5 3 2
Skull base/posterior fossa 40 15 15
Ventricular 4 1 1
Multiple 3 0
Histology
Meningothelial 28
Fibrous 26
Psammomatous 1
Transitional 19
Angiomatous 4
Microcystic 2
Atypical 30 30
Anaplastic 4 4
Unclassified 3
Ki-67 labeling index* 2.0  0.42 7.4  0.65 <0.001 5.9  3.7 <0.001 18.0  12.7
Malignancy index* 6.08  0.86 14.1  1.35 <0.001 12.5  11.2 <0.001 25.7  15.8
P values were obtained from c2 tests for categorical variables and one-way analysis of variance for continuous variables.
WHO, World Health Organization.
*Values are presented as mean  SD.
TECHNICAL NOTEconvexity dura mater with an irregular margin and peritumoral
edema (Figure 2A and B). The preoperative diagnosis was a
nonbenign type of histopathology. During surgery, the tumor
adhered strongly to the brain, and the arachnoid membrane
was not present as demarcation. Intraoperative histopathologic
examination of frozen tissue sections revealed mitoses and
necrotic changes. iFC analysis indicated a high MI of 12.3%
(Figure 2C), suggesting a grade II or III meningioma. We
performed gross total tumor resection, including the invaded
cortical interface of the cerebrum, based on the possibility of
malignant meningiomas. The final histopathologic diagnosis
after surgery was an atypical meningioma, WHO grade II, with
a Ki-67 immunohistochemistry result of 5.1% (Figure 2D).Illustrative Case 2
A 49-year-old man presenting with headache was referred to our
outpatient clinic. Magnetic resonance imaging revealed a tumor
extending along the cerebral falx and convexity dura mater with
an irregular margin and indentations toward the cerebral cortex,322 www.SCIENCEDIRECT.com WORLD NEsurrounded by peritumoral edema (Figure 3A and B). The
preoperative diagnosis was a nonbenign type of histopathology.
During surgery, the tumor adhered strongly to the brain, and
the arachnoid membrane was not present as demarcation.
Intraoperative histopathologic examination of frozen tissue
sections revealed no mitosis or necrotic change. iFC analysis
indicated a low MI of 5.8% (Figure 3C), indicating a grade I
meningioma. We performed gross total tumor resection except
for the wall of the sagittal sinus, the origin of the tumor, which
had just coagulated. The final histopathologic diagnosis after
surgery was meningothelial meningioma, WHO grade I, with a
Ki-67 immunohistochemistry result of 1.1% (Figure 3D).
DISCUSSION
The optimal treatment for all types of meningioma is complete
surgical excision, which is considered to result in the longest
recurrence-free and overall survival.1 For WHO grade II
meningiomas, the extent of their invasion into the brain and the
extent of their resection have been identified as prominentUROSURGERY, https://doi.org/10.1016/j.wneu.2018.08.084
Table 2. Clinical and Histologic Characteristics of Patients Who Underwent Tumor Removal for Intracranial Recurrent Meningioma
Age (Years)/Sex Location
Previous Surgery
Interval After
Last Surgery
(Months)
Present Surgery
Malignant
ChangeDiagnosis
WHO
Grade MIB-1 (%) iFC MI Diagnosis
WHO
Grade MIB-1 (%)
79/F Convexity Atypical 2 10.2 45 2.5 Atypical 2 9.2 No
75/F Parasagittal Anaplastic 3 21.4 42 26.7 Anaplastic 3 21.3 No
66/F Posterior cranial fossa Atypical 2 10.7 46 2.7 Atypical 2 5.2 No
48/F Multiple skull base Unclassifiable — — 204 8.8 Unclassifiable 1 1.6 —
67/F Trigone Unclassifiable — — 360 14.3 Fibrous 1 1 —
59/F Tentorium Atypical 2 4.7 36 19.4 Atypical 2 4.1 No
72/F Tuberculum sellae Meningothelial 1 3.7 19 6.3 Atypical 2 9.9 Yes
72/F Tuberculum sellae Meningothelial 1 7.7 9 13.7 Meningothelial 1 10.4 No
65/M Parasagittal Atypical 2 20.8 17 8.3 Atypical 2 20.8 No
65/F Convexity Anaplastic 3 14.3 123 15.4 Anaplastic 3 6.6 No
41/M Middle cranial fossa Fibrous 1 5 25 6.6 Atypical 2 5.3 Yes
46/F Tentorium Fibrous 1 1 28 5.1 Meningothelial 1 0.9 No
66/F Intraventricular Atypical 2 7.7 17 47.7 Anaplastic 3 34.5 Yes
WHO, World Health Organization; iFC, intraoperative flow cytometry; MI, malignancy index; F, female; M, male.
Figure 1. Receiver operating characteristic curve used to discriminate
between World Health Organization grade I and grade II/III meningiomas.
The area under the curve was 0.77.
TECHNICAL NOTEindependent factors associated with overall survival.17 In atypical
meningiomas, complete excision of the tumor alone is the most
important factor, and the additional excision of the affected
tissue and adjacent dura mater may be less important
compared with the extent of the tumor removal.18 Adjuvant
radiotherapy has been reported to improve disease-free survival
and overall survival19-22; conversely, other reports concluded that
radiotherapy did not prolong overall survival for patients with
grade II/III meningioma.4,17,23 A positive result of the NRG
Oncology RTOG 0539 trial was recently reported, and the
effectiveness of radiotherapy following the complete removal of
atypical meningiomas was demonstrated.24 Given these
findings, aggressive tumor removal increasingly appears to be
crucial for good treatment outcomes for grade II/III
meningiomas.17 Sun et al.18 proposed an algorithm for treating
atypical and anaplastic meningioma based on a literature
review and their data. However, not knowing the patient’s final
histopathologic diagnosis at the time of initial surgery poses a
particular dilemma when determining the appropriate treatment
strategy. If information on the degree of malignancy can be
obtained during the initial surgery, this would allow for the
determination of the optimal surgical technique for cases
where tumors strongly adhere to the brain surface, nerves,
vessels, and other vital structures.
Some reports have proposed radiologic features for the prediction
of grade II/III meningiomas preoperatively,4 including
heterogeneous enhancement,25 interdigitation with the brain,
significant bone destruction, a prominent pannus of tumor that
extends well away from the globoid mass (“mushrooming”),26
cyst formation, peritumoral edema, or the absence of
calcification with signs of heterogeneous enhancement.27
However, no radiologic imaging feature has been found to beWORLD NEUROSURGERY 120: 320-327, DECEMBER 2018strictly reliable for predicting the malignancy of
meningiomas.4,25-27 In our experience, it is difficult to distinguish
the level of malignancy before surgery, as is illustrated by the 2
cases described earlier.www.WORLDNEUROSURGERY.org 323
Figure 2. Case 1, illustrating the effectiveness of
intraoperative flow cytometry for a decision regarding
aggressive removal of a brain-invading tumor. (A)
Preoperative contrast-enhanced T1-weighted magnetic
resonance imaging showed a tumor extending along
the falx and convexity dura mater with an irregular
margin and interdigitation on the surface of the brain.
(B) T2-weighted magnetic resonance imaging showed
mixed intensity inside the tumor and peritumoral
edema at the lateral side of the tumor. (C) Malignancy
index calculated by intraoperative flow cytometry was
12.3%, a high value. (D) Hematoxylin and eosin staining
(200) revealed that tumor cells are accompanied by
whorl formation with increased cellularity. Necrosis and
mitotic figures are also recognized. This finding
confirmed grade II meningioma. The histopathologic
diagnosis was atypical meningioma, World Health
Organization grade II.
TECHNICAL NOTECell cycle kinetic and proliferative activity has been used in
evaluation of the malignancy of intracranial meningiomas to
predict biologic behavior, particularly the aggressiveness of the
meningioma.12-14 The cell cycle kinetic data evaluated by flow
cytometry appear suitable for distinguishing between grade I and
grade II/III meningiomas and for predicting the risk of tumor
recurrence. However, previous studies evaluating cell cycle
kinetics with flow cytometry have used paraffin-embedded ma-
terials.5-13 Several consensus reports noted that fresh or frozen
tumor tissues provide quicker and more reliable results than
paraffin-embedded materials.28,29
Lin et al.30 reported that intraoperative cell cycle analysis with
flow cytometry using fresh materials allowed grade I and grade
II/III meningiomas to be distinguished. However, their process
took >1 hour of preparation before the actual flow cytometric
analysis. In a similar report, Alexiou et al.31 described obtaining
an intraoperative diagnosis by flow cytometry within 6 minutes.
Their study focused on intracranial neoplasms, including a small
number of meningiomas (19 benign and 6 nonbenign). The324 www.SCIENCEDIRECT.com WORLD NEtechnique used in the present study was adapted from a
similar iFC technique described by Shioyama et al.15 for
evaluating gliomas using fresh material samples. In the present
study, new equipment with a higher degree of automation
facilitated the process, and only 9 minutes was required for the
evaluation of the malignancy of meningiomas by iFC.
The expression of Ki-67 monoclonal antibodies correlates posi-
tively with histologic malignancy and the risk of recurrence, and
Ki-67 analyses have been widely used in clinical practice.32
However, the Ki-67 staining method has not been universally
standardized and cannot discriminate clearly between grade I and
grade II/III meningiomas.33 Several reports have indicated that Ki-
67 results showed no significant correlation with the outcome of
grade II meningiomas after resection.28,34,35
Alexiou et al.14 reported rapid examination methods using flow
cytometry, which discriminated between benign and nonbenign
meningiomas using 3 parameters: G0/G1 phase, S phase, and
mitoses fraction. However, our method was simpler because itUROSURGERY, https://doi.org/10.1016/j.wneu.2018.08.084
Figure 3. Case 2, illustrating the effectiveness of
intraoperative flow cytometry for a decision regarding
aggressive removal of a brain-invading tumor. (A)
Preoperative contrast-enhanced T1-weighted magnetic
resonance imaging showed the tumor extending along
the falx and convexity dura mater with an irregular
margin and interdigitation on the surface of the brain.
(B) T2-weighted magnetic resonance imaging showed
mixed intensity inside the tumor and peritumoral
edema. (C) Malignancy index calculated by
intraoperative flow cytometry was 5.8%, a low value.
(D) Hematoxylin and eosin staining (200) revealed no
malignant findings. The histopathologic diagnosis was
meningothelial meningioma, World Health Organization
grade I.
TECHNICAL NOTEwas performed according to the manufacturer’s instructions,
with the degree of malignancy calculated automatically as the
MI. Our method is based on aggressive neoplasms having
more proliferative cells with high values for the S and G2/M
phases or more aneuploid cells.5,12,14,15 Our results demon-
strated a statistically significant association between the MI
values and the grade of meningioma. According to the ROC
analysis, an MI of 8.0% was the optimal cutoff value for
discriminating between WHO grade I and grade II/III meningi-
omas. The relatively high specificity (85.0%) of this method
supports the effectiveness of using MI based on iFC as an
adjuvant diagnostic method to determine the grade II/III menin-
giomas. However, the relatively low sensitivity (64.7%) suggests
the possibility of false-negative results during detection of grade
II/III meningiomas. There is no single perfect inspection instru-
ment, and a general additional evaluation was still required,
including preoperative radiographic findings and the assessment
of intraoperative frozen tissue and Ki-67 immunohistochemical
findings by a pathologist.
This study has several limitations. It was performed at a single
institution. Apoptosis or necrosis owing to high malignancy canWORLD NEUROSURGERY 120: 320-327, DECEMBER 2018potentially result in the loss of DNA, leading to low estimates. The
relatively low sensitivity (64.7%) may be the result of these path-
ologic changes. Only 4 of the patients had anaplastic meningi-
omas; a larger number of cases in this subgroup are needed for a
proper evaluation of the method. The MI indicates only the ma-
lignancy of the tumor cells themselves and does not reveal any
information regarding invasiveness of the tumors to the brain.
Therefore, the MI cannot detect WHO grade II tumors diagnosed
based on the evidence of the invasion of the brain according to the
WHO grading since 2007. As this study was conducted in a pro-
spective and cohort manner, clinical results, such as the relation-
ship between theMI and the prognosis or recurrence rate, remain
unclear because of the short follow-up period. This should be
clarified in the future by a longer follow-up period.
CONCLUSIONS
Our novel method, based on determining the MI using iFC, was
shown to be technically feasible and reliable for ultrarapid eval-
uation of malignancy of meningiomas. MI values differed signif-
icantly between WHO grade I and grade II/III meningiomas. The
cell processing algorithm used in this method is based on thewww.WORLDNEUROSURGERY.org 325
TECHNICAL NOTEmanufacturer’s instructions, and the analysis can be completed
within 9 minutes. Being able to distinguish nonbenign from
benign meningiomas intraoperatively could improve patient
prognosis by allowing neurosurgeons to determine the appro-
priate aggressiveness needed for addressing the tumor and in-
vasion to the brain, nerves, and vessels. However, further
studies are needed to assess the association between MI and
prognosis or recurrence rate.326 www.SCIENCEDIRECT.com WORLD NEACKNOWLEDGMENTS
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